Verified peer comparison

JNJ vs LLY

Johnson & Johnson compared with Eli Lilly and Company. This page compares both source-verified company profiles and does not introduce an unverified price target.

JNJ

Johnson & Johnson

$189.43

Open
--
High
--
Low
--
Market Cap
--
Open stock research

LLY

Eli Lilly and Company

$782.10

Open
--
High
--
Low
--
Market Cap
--
Open stock research

Company-specific comparison

Business exposure

JNJ: Pharmaceuticals

LLY: Pharmaceuticals

Upside lens

JNJ: Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products. Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth. Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

LLY: obesity drug adoption and pipeline expansion

Risk lens

JNJ: Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts. Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines. Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

LLY: supply constraints and valuation expectations

Verified sources

Johnson & Johnson 2026 First-Quarter ResultsJohnson & Johnson · earningsVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/14/2026, 10:45:00 AM

Open original source
Johnson & Johnson Investor RelationsJohnson & Johnson · companyVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Open original source
Johnson & Johnson Form 10-Q for the fiscal quarter ended March 29, 2026U.S. Securities and Exchange Commission · filingVerified

Fetched: 7/12/2026, 12:00:00 AM UTC

Published: 4/22/2026, 12:00:00 AM

Open original source
Lilly Reports First-Quarter 2026 Financial ResultsEli Lilly and Company · earningsVerified

Fetched: 7/11/2026, 12:00:00 AM UTC

Published: 4/30/2026, 12:00:00 AM

Open original source
Eli Lilly Investor RelationsEli Lilly and Company · companyVerified

Fetched: 7/11/2026, 12:00:00 AM UTC

Open original source
Form 10-Q for the Quarter Ended March 31, 2026Eli Lilly and Company · filingVerified

Fetched: 7/11/2026, 12:00:00 AM UTC

Published: 4/30/2026, 12:00:00 AM

Open original source
LLY editorial research profileAlphaVue Research · editorialVerified

Fetched: 7/11/2026, 12:00:00 AM UTC